Atommap

Atommap is a private, pre-clinical stage biotech company pioneering a computational approach to drug discovery centered on simulating and harnessing the dynamic motion of proteins. Its proprietary platform integrates molecular dynamics, generative AI, and predictive computational assays to design novel therapeutic modalities, particularly molecular glues and targeted protein degraders, for historically undruggable targets. Founded by veterans from D. E. Shaw Research, Schrödinger, and Silicon Therapeutics, the company is advancing a pipeline in oncology, exemplified by case studies on mutant KRAS and SMARCA2.

Integrated computational platform combining molecular dynamics simulations for target insights (modeling biomolecular motion), generative AI for molecular design (of glues/degraders), and predictive computational assays for virtual screening of binding affinity and functional outcomes (e.g., degradation efficacy).

Atommap competes in the crowded AI-driven drug discovery space against public companies like Schrödinger and Recursion, and numerous private AI-biotechs (e.g., Genesis, Isomorphic Labs). Its specific focus on molecular dynamics for degrader design differentiates it, but it must compete for talent, data, and partnerships with these well-resourced entities.